The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NFX | +215.79% | -90.77% | -37.91% | -94% |
| S&P | +14.43% | +77.25% | +12.13% | +171% |
Nuformix Plc is a pharmaceutical development company, which targets unmet medical needs in fibrosis and oncology via drug repurposing. It focuses on cocrystal technology. Its products include NXP001, NXP002, and NXP004. The company was founded by Joanne Holland, Daniel Gooding, and David Tapolczay in 2008 and is headquartered in London, the United Kingdom.
No news articles found for Nuformix Plc.
No data available for this period.
Currently no data to display
Currently no data to display.
Currently no data to display.
No data available for this period.
No data available for this period.
No data available for this period.
No data available for this period.
| Metric | YoY Change |
|---|
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
